DUBLIN–(BUSINESS WIRE)–“A Practical Guide to Writing Risk Management Plans (RMPs) Training Course (Mar 20, 2026)” has been added to ResearchAndMarkets.com’s offeringDUBLIN–(BUSINESS WIRE)–“A Practical Guide to Writing Risk Management Plans (RMPs) Training Course (Mar 20, 2026)” has been added to ResearchAndMarkets.com’s offering

A Practical Guide to Writing Risk Management Plans (RMPs) Training Course: Advice on EU Risk Management Plans for New Products (Mar 20, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–“A Practical Guide to Writing Risk Management Plans (RMPs) Training Course (Mar 20, 2026)” has been added to ResearchAndMarkets.com’s offering.

In the EU, all companies are required to provide risk management plans (RMPs) for every new product, whether generic products or new chemical entities, and these RMPs must also be modified and updated throughout the lifetime of a medicine.

This intensive one-day course will provide you with an invaluable overview of writing and maintaining RMPs, with practical advice to ensure you achieve regulatory compliance. You will discuss best practice for using the EU templates and risk minimisation tools to enhance the benefit/risk of your product.

The programme has been fully revised to cover the latest updates and new requirements, including amendments made to the previous template.

Benefits of attending:

  • Gain an overview of ICH and EU RMPs – their production and ongoing maintenance
  • Clarify the documentation to be supplied to regulators and the process for RMPs
  • Learn what happened in the EU RMP update and explore the new requirements
  • Discuss the EU templates and their completion – generic and innovative products
  • Understand the relationship between RMPs, post-authorisation safety and efficacy studies, safety reviews and PBRERs
  • Discuss the RMP and risk minimisation follow-up

Who Should Attend:

This course will be relevant for those working in pharmacovigilance who are involved with writing RMPs, including medical directors/QPPVs who approve such plans. It will also be of interest to those who work with pharmacovigilance, e.g. in regulatory affairs, clinical, pre-clinical, sales and marketing, legal, commercial and quality.

Certification:

  • CPD: 6 hours for your records
  • Certificate of completion

Key Topics Covered:

Introduction, welcome and objectives

An introduction to RMPs

  • Outline and purpose of ICH E2E
  • The implementation of ICH E2E
  • National adoption of ICH E2E
    • Europe
    • USA
    • Japan
    • Arab States

Outline of EU RMPs

  • The current EU module V requirements
  • Generic, innovator and advanced therapy products
  • Additional documents to supply to the regulators
  • Safety reporting timelines for RMPs
  • EU RMP update and new requirements

The EU templates and their completion – generic and innovator products

  • The EU generic template – EU requirements (module V)
  • The EU generic RMP versus innovator RMP
  • The EU template for innovator products

Completion of RMPs in other countries

The EU RMP and relationship with other documents

  • The RMP post-authorisation safety and efficacy studies
  • The RMP and PBRERs
  • The RMP and safety reviews

The RMP and Risk Minimisation Follow up

Overview of the sections of the EU RMP template

  • Part I – Product overview
  • Part II – Safety specification modules SI-SVIII
  • Part III – Pharmacovigilance plan including safety studies
  • Part IV – Plans for post-authorisation efficacy studies
  • Part V – Risk minimisation activities including effectiveness measures
  • Part VI – Summary of the risk management plan
  • Part VII – Annexes

Final discussion session

Speakers:

Graeme Ladds

Director

PharSafer Associates Ltd.

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

For more information about this training visit https://www.researchandmarkets.com/r/2w60ad

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Coinbase Joins Ethereum Foundation to Back Open Intents Framework

Coinbase Joins Ethereum Foundation to Back Open Intents Framework

Coinbase Payments has joined the Open Intents Framework as a core contributor, working alongside Ethereum Foundation and other major players. The initiative aims to simplify complex multi-chain interactions through automated solver technology. The post Coinbase Joins Ethereum Foundation to Back Open Intents Framework appeared first on Coinspeaker.
Share
Coinspeaker2025/09/18 02:43
SBI Holdings introduces SBI Hyper Deposit with XRP gifts and rate cuts

SBI Holdings introduces SBI Hyper Deposit with XRP gifts and rate cuts

The post SBI Holdings introduces SBI Hyper Deposit with XRP gifts and rate cuts appeared on BitcoinEthereumNews.com. Key Takeaways SBI Holdings has introduced ‘SBI Hyper Deposit’, automating transfers between bank and securities accounts. Launch incentives include XRP cryptocurrency gifts and reduced mortgage rates for early adopters. SBI Holdings launched “SBI Hyper Deposit,” a new service that automates transfers between bank and securities accounts. The Japanese financial services company is offering launch incentives including XRP gifts and reduced mortgage rates to customers who sign up for the automated transfer system. The service is designed to streamline the movement of funds between different SBI financial products, allowing customers to manage their banking and investment accounts more efficiently through automated transfers. Source: https://cryptobriefing.com/sbi-holdings-hyper-deposit-xrp-incentive/
Share
BitcoinEthereumNews2025/09/18 20:52
Two Prime selected to manage $250 million in bitcoin for Digital Wealth Partners

Two Prime selected to manage $250 million in bitcoin for Digital Wealth Partners

The institutional bitcoin manager expands its mandate as demand for professional risk-managed digital asset strategies grows.
Share
Coinstats2026/01/16 18:00